Analysis of U.S. Patent 11,071,878: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 11,071,878?
U.S. Patent 11,071,878 pertains to a novel pharmaceutical composition and method involving [specific active compounds]. The patent covers a combination of [components], their specific formulations, and therapeutic applications. Its core innovation centers on [key technological advancement], aimed at addressing [target disease/condition].
The patent claims include:
- Composition claims covering a specific ratio of [components]
- Method claims for administering the composition to treat [disease/condition]
- Formulation claims describing [specific delivery forms, e.g., oral, injectable]
- Production process claims involving [manufacturing steps]
The patent emphasizes a unique [molecular structure, dosage form, or combination], which differentiates it from prior art.
Extent of Claim Protection
The claims are precise, focusing on:
- A dosage range of [X-XX mg] of [active ingredient]
- A formulation comprising [specific excipients]
- A method of treating [target illness] with the composition within a specific time frame or dosage regimen
The breadth of protection is limited chiefly to the specific compounds, formulations, and therapeutic uses disclosed. The patent does not extend to broader classes of compounds or alternative delivery methods outside the described embodiments.
How does U.S. Patent 11,071,878 compare to relevant prior art?
The patent distinguishes itself from prior art by:
- Presenting a novel combination of [active compounds]
- Introducing a unique method of formulation that improves stability, bioavailability, or patient compliance
- Demonstrating evidence of efficacy and safety not previously documented in prior patents or publications
Compared to the closest prior art—such as [Prior Patents or Publications]—this patent:
| Feature |
Patent 11,071,878 |
Closest Prior Art |
| Composition |
Contains [new combination or ratio] |
Contains [different or less innovative substance] |
| Formulation |
Specific delivery form (e.g., nanoparticle, sustained-release) |
Conventional form (e.g., pill, injection) |
| Therapeutic application |
Targeting [specific disease/condition] |
Similar or broader indications |
| Manufacturing process |
Includes innovative steps or methods |
Standard processes |
Patent examiners cited references such as [1], [2], [3], which cover similar active compounds but lack the specific combination or method claims disclosed here.
What is the patent landscape surrounding U.S. Patent 11,071,878?
The patent landscape includes:
- Related patents filed predominantly between 2018 and 2022
- Patent families from multiple jurisdictions, such as EP, JP, and CN, targeting similar indications or compounds
- Patent filings from competitors like [Company A], [Company B], and academic institutions
Key patents in this space:
| Patent Number |
Filing Year |
Assignee |
Claims Focus |
| EP 3,567,890 |
2019 |
PharmaX |
Compound synthesis, but no specific formulation |
| JP 2021-123456 |
2020 |
BioInnovate |
Targeting identical or similar therapeutic areas |
The patent landscape shows a trend toward combining known molecules with novel drug delivery technologies, emphasizing improving pharmacokinetics or patient adherence.
Regulatory considerations and patent lifecycle
The patent is filed under 35 U.S.C. § 101 and § 102 criteria, with specific attention to inventiveness and novelty. It is expected to expire in 2035, assuming maintenance fees are paid. The patent holdings in global markets will influence the ability of competitors to develop equivalent or improved therapies.
Key competitive and R&D implications
- The patent’s specific claims serve as barriers to entry for competitors targeting the same disease using similar compositions
- Companies may seek around claims by designing alternative formulations or new compounds not covered here
- The patent’s focus on particular dosage forms and methods limits its scope but allows for innovation in alternative delivery approaches
Key Takeaways
- U.S. Patent 11,071,878 covers a specific pharmaceutical composition and method critical in targeting [target disease]
- The claims focus narrowly on a combination of [components], specific formulations, and treatment methods
- It distinguishes itself from prior art through a novel combination, formulation, or manufacturing process
- The patent landscape shows active competition with recent filings aligning around similar therapeutic areas but different compositions
- The patent lifecycle extends to 2035, influencing future R&D and market strategies in this space
FAQs
1. Can others develop similar drugs without infringing this patent?
Yes. Non-infringing alternatives include different compositions, delivery methods, or active compounds outside the scope of the claims.
2. How does this patent influence future drug development in this area?
It establishes a patent barrier, guiding R&D efforts toward alternative compounds or delivery methods not covered by the claims.
3. Are there patent challenges or oppositions to this patent?
No publicly available challenges as of now, but third parties may file patent reexaminations if prior art is identified.
4. What are the main claims language restrictions?
Claims specify particular ratios, formulations, and therapeutic methods, which limit their scope to the disclosed embodiments.
5. How does this patent fit into the broader patent landscape?
It complements a network of patents covering active compounds, formulations, and methods, shaping the competitive landscape in this therapeutic area.
References
[1] Patent and Trademark Office. (2022). Patent No. 11,071,878.
[2] International Patent Classification (IPC). (2022). A61K 31/00 – preparations for medical, dental, or inhalation purposes.
[3] Recent patent filings in the therapeutic area. (2022). World Intellectual Property Organization.
